|
|
Post by brentie on Nov 25, 2023 4:50:40 GMT -5
|
|
|
|
Post by sportsrancho on Nov 25, 2023 7:12:43 GMT -5
|
|
|
|
Post by Clement on Nov 25, 2023 8:33:23 GMT -5
Early in the article, speaking of Mannkind's commercial products he says,
"Gross Net Revenue for four quarters or a full year time frame-$71.274M
Monthly Average Over this Period --$17.818M"
That's two lies (or mistakes) in a row: It's not "Gross Net Revenue". And it's not a "Monthly Average". I stopped reading at that point.
You can find the actual numbers on page 35 of the 10Q.
|
|
|
|
Post by uvula on Nov 25, 2023 9:03:44 GMT -5
That article is soooo long. Is attacking mnkd his full time job?
|
|
|
|
Post by sportsrancho on Nov 25, 2023 11:16:41 GMT -5
I wish someone would write a rebuttal!
|
|
|
|
Post by hopingandwilling on Nov 25, 2023 12:08:36 GMT -5
Clement,
I haven't posted here for what is about a year (I think) but this morning before the football games, I opted to look what was being said about Mannkind.
I would be the last person to defend (she/him) LDFD but in your post you imply (she/him) is wrong about the revenue data shown. (She/Him) is a little wordy and did miss spell one word in the article---(Pring vs Print). However, you might not have noticed but in your first sentence of rebuttal it appears and is clearly stated that the net revenue number (She/He) mentioned were for MannKind's commercial products---that being Afrezza and V-Go. All the other revenue is for services.
Now back to my lurking!
|
|
|
|
Post by agedhippie on Nov 25, 2023 12:38:36 GMT -5
I wish someone would write a rebuttal! It was a bit of a disappointment. I quite like LFD's articles because they present another view that I might disagree with, but which has some sort of point to consider. This one - not so much. LFD desperately needs an editor to structure his articles. His entire article could be summarized as: - Afrezza is in the doldrums - V-Go is deadweight - UTHR will unhesitatingly screw over MNKD to improve their margins to compete with Merck and LQDA. - Clofazimine is nasty and the FDA will probably make MNKD do analysis on the impact on the lungs - If your product is dry powder then using a nebulizer for your new product isn't a great advert. - With the wrap up that this is going to lead to cash problems for MNKD. My read is that it's a statement of the obvious. Yes Afrezza is in the doldrums, and V-Go as a product is going nowhere but anyone can see that (Mike has made the argument though that V-Go was also about buying an established sales organization.) A proper analysis of the competitive landscape for UTHR in the PAH/PH-ILD market would have been good, but instead we got a grab bag of random facts presented as a case. Clofazimine is undoubtably nasty, but that is what MNKD is attempting to address. I will wait for the trial results to see if inhaling Clofazimine addresses the systemic issues. I do agree that the FDA may want to know more about the impact on the lungs given the impact on skin (this was probably the only bit I thought was interesting). The nebulizer argument sort of has a point. It feels like they are using a nebulizer because that's what all the work to date has been done using and they don't want to switch. The argument about crystals clogging the lings is bizarre given how Technosphere works. That's an initial thought on a very long winded article. Ideal that should have been three separate article for clarity made up of the first two points, the third point, and the fourth point. |
|
|
|
Post by liane on Nov 25, 2023 14:40:13 GMT -5
Sorry @sportsrancho - due to copyright stuff, we can't post the whole article here. But people should be able to read it by following the link. I was able to. |
|
|
|
Post by sportsrancho on Nov 25, 2023 15:26:21 GMT -5
Thanks aged❣️ that’s all anyone needs to read.
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Nov 25, 2023 20:04:07 GMT -5
Yes, thank you, Aged
|
|
|
|
Post by mango on Nov 27, 2023 15:34:43 GMT -5
Why is LFD so obsessed with MannKind? I realize he’s got a position in a competitor stock (Liquidia) but how does that explain the past 10+ years of hit pieces? Something is fishy.
|
|
|
|
Post by sayhey24 on Nov 28, 2023 18:49:58 GMT -5
Mango - I think its as simple as ego. For 10 years he has predicted bankrupty for MNKD and it has not happened. I think he jumped back in thinking with the debt coming due, now will be the time.
He raises some fair points in his article which include V-Go is a dud and Mike's pipeline will not produce a blockbuster. He also complains Mike is getting paid to much for what he has delivered. I agree with him on all three points.
Where we differ is I still believe in the potential of afrezza and he still does not really understand why afrezza is so different. If you and I are correct we will have a winner here. His assumption is Mike will never figure out how to sell it. The reality to date is, he is right and Mike has not been able to sell afrezza. 2024 will be the year. If the 3 trials end well and Mike jumps into the GLP1 game we are off to the races. If this time next year Mike is still clinging to V-Go and his existing pipeline MNKD may not go bankrupt but it sure will not be a taking off like a rocket.
BTW - Aged made a comment about V-Go that Mike has made the argument that V-Go was also about buying an established sales organization. I am pretty sure I heard Mike say they have again re-organized the sales division and its down to 70 reps total. I think this was part of the attempt to "stabilize" V-Go.
|
|
|
|
Post by prcgorman2 on Dec 4, 2023 10:39:48 GMT -5
I wish someone would write a rebuttal! It was a bit of a disappointment. I quite like LFD's articles because they present another view that I might disagree with, but which has some sort of point to consider. This one - not so much. LFD desperately needs an editor to structure his articles. His entire article could be summarized as: - Afrezza is in the doldrums - V-Go is deadweight - UTHR will unhesitatingly screw over MNKD to improve their margins to compete with Merck and LQDA. - Clofazimine is nasty and the FDA will probably make MNKD do analysis on the impact on the lungs - If your product is dry powder then using a nebulizer for your new product isn't a great advert. - With the wrap up that this is going to lead to cash problems for MNKD. My read is that it's a statement of the obvious. Yes Afrezza is in the doldrums, and V-Go as a product is going nowhere but anyone can see that (Mike has made the argument though that V-Go was also about buying an established sales organization.) A proper analysis of the competitive landscape for UTHR in the PAH/PH-ILD market would have been good, but instead we got a grab bag of random facts presented as a case. Clofazimine is undoubtably nasty, but that is what MNKD is attempting to address. I will wait for the trial results to see if inhaling Clofazimine addresses the systemic issues. I do agree that the FDA may want to know more about the impact on the lungs given the impact on skin (this was probably the only bit I thought was interesting). The nebulizer argument sort of has a point. It feels like they are using a nebulizer because that's what all the work to date has been done using and they don't want to switch. The argument about crystals clogging the lings is bizarre given how Technosphere works. That's an initial thought on a very long winded article. Ideal that should have been three separate article for clarity made up of the first two points, the third point, and the fourth point. I hope LFD doesn't read ProBoards or see your sensible advice on how to write better hit pieces.
I have often wondered what it must be like to sit with a bunch of guys with doctorates in pharma trying to figure out what are the best candidates for the MannKind pipeline from what I will call a compounding perspective (reflecting viability of Technosphere + some drug), a medical benefit perspective, and a corporate shareholder value perspective.
I never assumed Clofazamine would be a slam dunk and I don't believe in slam dunks except for folks like Pfizer and BioNTech under exceptional emergency circumstances. Short of that, getting things approved by the FDA is well known for being more difficult than many other places on the planet.
I've also wondered if the choice of nebulized Clofazamine was an outcome from discussion with the FDA about "orphan drug" status and Phase 1 and Phase 2/3 testing. I recall that the FDA dominated the (awful) design of the 3rd Afrezza trial and I can't help but be concerned any drug MannKind takes forward has that same possibility of badly handled regulatory oversight.
I've also thought the study design of days on, days off with Clofazamine was some attempt to improve compliance and outcomes in the presence of a treatment with undesirable side-effects.
All that being said, from what I've read and based on comments from stevil , treating Non-Tuberculosis Mycobacterium is non-trivial and Clofazamine could be a very valuable therapy. I hope it is for the sake of sufferers of NTM. |
|
|
|
Post by cretin11 on Dec 4, 2023 11:13:32 GMT -5
Pretty sure LFD reads ProBoards  |
|
|
|
Post by parrerob on Feb 15, 2024 8:23:33 GMT -5
|
|
